The primary objective is to compare surgery with postoperative radiotherapy (PORT) versus surgery, in terms of the overall survival time (OS) in Stage II or III squamous cell esophageal carcinoma with neoadjuvant chemoradiotherapy(nCRT).
Patients must not have received any prior anticancer therapy Histologically-confirmed squamous cell carcinoma of the esophagus;
Tumors of the esophagus are located in the thoracic cavity;
Pre-treatment stageⅡ-Ⅲ (AJCC/UICC 8th Edition)
Male or non pregnant female
Patients with non-squamous cell carcinoma histology;
Patients with advanced inoperable or metastatic esophageal cancer;
Patients with another previous or current malignant disease；
Any patient with a significant medical condition which is thought unlikely to tolerate the therapies. Such as cardiac disease;